NCT01885897View on ClinicalTrials.gov

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 11, 2013

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2020

Conditions
Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndromes (MDS)LymphomaMyelomaChronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)
Interventions
BIOLOGICAL

ALT-803

Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

63110

Washington University, St Louis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Biotech Hunter | Biotech Hunter